{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-005988","form_type":"8-K","ticker":"PAYS","cik":"0001496443","company_name":"Paysign, Inc.","filed_at":"2026-08-05T20:05:47+00:00","discovered_at":"2026-08-05T20:07:00.324022+00:00","generated_at":"2026-08-05T20:08:06.942789+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Paysign reports record Q2 revenue $28.3M (+48%), raises FY2026 outlook","bullets":["Revenue $28.25M, up 48.1% YoY; GAAP net income $6.76M ($0.11 EPS) vs $1.39M ($0.02) prior year.","Pharma revenue $14.65M (+88.9%) with 148 active programs; plasma revenue $13.04M (+21.4%) with 561 centers.","Adjusted EBITDA $9.61M, up 113%; operating margin 24.8% (21.3% ex contingent consideration).","Raised FY2026 revenue guidance to $114-117M and adjusted EBITDA to $35-38M.","Balance sheet: $27.37M unrestricted cash, zero bank debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-005988","json":"https://secwatch.observer/filing/0001683168-26-005988.json","markdown":"https://secwatch.observer/filing/0001683168-26-005988.md","text":"https://secwatch.observer/filing/0001683168-26-005988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496443/000168316826005988/0001683168-26-005988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496443/000168316826005988/paysign_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:08:06.942789+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}